Dage, Jeffrey L.

Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders

Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,603

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,247

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 761

Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

Mielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 621

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 607

Blood biomarkers for Alzheimer’s disease in clinical practice and trials

Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 522

Performance of plasma phosphorylated tau 181 and 217 in the community

Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 465

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 450

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

Brickman, A. M., Manly, J. J., Honig, L. S., Sanchez, D., Reyes‐Dumeyer, D., Lantigua, R. A., Lao, P. J., Stern, Y., Vonsattel, J. P., Teich, A. F., et al. (2021) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 387

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., Mengel, D., Walsh, D. M., Stomrud, E., Dage, J. L., et al. (2020) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 368

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease

Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 359

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 353

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 353

Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions

Sieberts, S. K., Perumal, T. M., Carrasquillo, M. M., Allen, M., Reddy, J. S., Hoffman, G. E., Dang, K. K., Calley, J., Ebert, P. J., Eddy, J., et al. (2020) · Scientific Data

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 318

Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape

Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 283

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

Mattsson‐Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G., et al. (2021) · EMBO Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 261

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Pontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 261

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

Mielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 244

Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance

Pichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 226

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 188

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

Cullen, N. C., Leuzy, A., Palmqvist, S., Janelidze, S., Stomrud, E., Pesini, P., Sarasa, L., Allué, J. A., Proctor, N. K., Zetterberg, H., et al. (2020) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 187

Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population‐based elderly cohort

Dage, J. L., Wennberg, A. M. V., Airey, D. C., Hagen, C. E., Knopman, D. S., Machulda, M. M., Roberts, R. O., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 145

Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays

Leuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 128

Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model

Wang, H., Li, Y., Ryder, J. W., Hole, J. T., Ebert, P. J., Airey, D. C., Qian, H.-R., Logsdon, B., Fisher, A., Ahmed, Z., et al. (2018) · Molecular Neurodegeneration

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 83